The FDA granted approval for Journavx after clinical trials demonstrated its effectiveness in post-surgical pain relief ...

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...

A new study has found that adults with newly diagnosed sciatica who received chiropractic spinal manipulation (CSM) were significantly less likely to experience opioid-related adverse drug events ...

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...

A new type of non-opioid painkiller, aimed at treating short-term pain in adults, has been approved by the US Food and Drug ...

The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

The U.S. Food and Drug Administration (FDA) on Thursday approved Journavx, the first new class of pain medication in more ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...